Angiotensin 1–7 and the Non-Peptide MAS-R Agonist AVE0991 Inhibit Breast Cancer Cell Migration and Invasion

<b>Background:</b> Endocrine resistance in breast cancer is associated with the epithelial-to-mesenchymal transition (EMT), resulting in enhanced cell proliferation, motility, and invasion and leading to a poor prognosis. There are few studies regarding the role of Angiotensin II (Ang II...

Full description

Saved in:
Bibliographic Details
Main Authors: Mariam M. Alfoudiry, Maitham A. Khajah
Format: Article
Language:English
Published: MDPI AG 2025-02-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/13/3/567
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850205500117876736
author Mariam M. Alfoudiry
Maitham A. Khajah
author_facet Mariam M. Alfoudiry
Maitham A. Khajah
author_sort Mariam M. Alfoudiry
collection DOAJ
description <b>Background:</b> Endocrine resistance in breast cancer is associated with the epithelial-to-mesenchymal transition (EMT), resulting in enhanced cell proliferation, motility, and invasion and leading to a poor prognosis. There are few studies regarding the role of Angiotensin II (Ang II) and Angiotensin 1–7 (Ang 1–7) in relation to breast cancer, with contradictory outcomes. This study aims to investigate the expression of Ang 1–7 and MAS-R and evaluate the effects of Ang II, Ang 1–7, and the MAS-R agonist AVE0991 on EMT induction and reversal. <b>Methods:</b> The effects of Ang II and Ang 1–7 on normal and breast cancer cell lines were determined using various techniques for cell proliferation (MTT), motility (scratch assay), and invasion (Cultrex assay). Also, the expression/localization profiles of Ang 1–7 and its receptor (MAS-R), as well as various EMT markers, were determined using immunofluorescence, western blot, and ELISA. <b>Results:</b> Ang II significantly decreased the motility of the tested cell lines; however, it did not have a significant effect on their proliferation or invasion. The expression profiles of the tested EMT markers were not affected by Ang II treatment. The expression levels of Ang 1–7 and MAS-R were significantly higher in the normal breast epithelial cells and estrogen receptor ER compared to the ER+ breast cancer cells. Treatment with Ang 1–7 or the non-peptide MAS-R agonist AVE0991 significantly reduced the migration and invasion of the tested cell lines without modulating the tested EMT markers. Compared to Ang 1–7, AVE0991 exhibited a more prominent dose-dependent inhibitory effect on the proliferation, motility, and invasion of the ER− breast cancer cells. <b>Conclusions:</b> Ang 1–7 and AVE0991 play a promising therapeutic role in breast cancer, in part by reducing cell motility and invasion.
format Article
id doaj-art-db7d047b41424e5d85c9f3b0abf3347b
institution OA Journals
issn 2227-9059
language English
publishDate 2025-02-01
publisher MDPI AG
record_format Article
series Biomedicines
spelling doaj-art-db7d047b41424e5d85c9f3b0abf3347b2025-08-20T02:11:04ZengMDPI AGBiomedicines2227-90592025-02-0113356710.3390/biomedicines13030567Angiotensin 1–7 and the Non-Peptide MAS-R Agonist AVE0991 Inhibit Breast Cancer Cell Migration and InvasionMariam M. Alfoudiry0Maitham A. Khajah1Department of Pharmacology and Therapeutics, College of Pharmacy, Kuwait University, P.O. Box 24923, Safat 13110, KuwaitDepartment of Pharmacology and Therapeutics, College of Pharmacy, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait<b>Background:</b> Endocrine resistance in breast cancer is associated with the epithelial-to-mesenchymal transition (EMT), resulting in enhanced cell proliferation, motility, and invasion and leading to a poor prognosis. There are few studies regarding the role of Angiotensin II (Ang II) and Angiotensin 1–7 (Ang 1–7) in relation to breast cancer, with contradictory outcomes. This study aims to investigate the expression of Ang 1–7 and MAS-R and evaluate the effects of Ang II, Ang 1–7, and the MAS-R agonist AVE0991 on EMT induction and reversal. <b>Methods:</b> The effects of Ang II and Ang 1–7 on normal and breast cancer cell lines were determined using various techniques for cell proliferation (MTT), motility (scratch assay), and invasion (Cultrex assay). Also, the expression/localization profiles of Ang 1–7 and its receptor (MAS-R), as well as various EMT markers, were determined using immunofluorescence, western blot, and ELISA. <b>Results:</b> Ang II significantly decreased the motility of the tested cell lines; however, it did not have a significant effect on their proliferation or invasion. The expression profiles of the tested EMT markers were not affected by Ang II treatment. The expression levels of Ang 1–7 and MAS-R were significantly higher in the normal breast epithelial cells and estrogen receptor ER compared to the ER+ breast cancer cells. Treatment with Ang 1–7 or the non-peptide MAS-R agonist AVE0991 significantly reduced the migration and invasion of the tested cell lines without modulating the tested EMT markers. Compared to Ang 1–7, AVE0991 exhibited a more prominent dose-dependent inhibitory effect on the proliferation, motility, and invasion of the ER− breast cancer cells. <b>Conclusions:</b> Ang 1–7 and AVE0991 play a promising therapeutic role in breast cancer, in part by reducing cell motility and invasion.https://www.mdpi.com/2227-9059/13/3/567breast cancerEMTendocrine resistanceAng IIAng 1–7AVE0991
spellingShingle Mariam M. Alfoudiry
Maitham A. Khajah
Angiotensin 1–7 and the Non-Peptide MAS-R Agonist AVE0991 Inhibit Breast Cancer Cell Migration and Invasion
Biomedicines
breast cancer
EMT
endocrine resistance
Ang II
Ang 1–7
AVE0991
title Angiotensin 1–7 and the Non-Peptide MAS-R Agonist AVE0991 Inhibit Breast Cancer Cell Migration and Invasion
title_full Angiotensin 1–7 and the Non-Peptide MAS-R Agonist AVE0991 Inhibit Breast Cancer Cell Migration and Invasion
title_fullStr Angiotensin 1–7 and the Non-Peptide MAS-R Agonist AVE0991 Inhibit Breast Cancer Cell Migration and Invasion
title_full_unstemmed Angiotensin 1–7 and the Non-Peptide MAS-R Agonist AVE0991 Inhibit Breast Cancer Cell Migration and Invasion
title_short Angiotensin 1–7 and the Non-Peptide MAS-R Agonist AVE0991 Inhibit Breast Cancer Cell Migration and Invasion
title_sort angiotensin 1 7 and the non peptide mas r agonist ave0991 inhibit breast cancer cell migration and invasion
topic breast cancer
EMT
endocrine resistance
Ang II
Ang 1–7
AVE0991
url https://www.mdpi.com/2227-9059/13/3/567
work_keys_str_mv AT mariammalfoudiry angiotensin17andthenonpeptidemasragonistave0991inhibitbreastcancercellmigrationandinvasion
AT maithamakhajah angiotensin17andthenonpeptidemasragonistave0991inhibitbreastcancercellmigrationandinvasion